Envestnet Asset Management Inc. grew its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 1.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 736,326 shares of the company’s stock after buying an additional 12,545 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Genmab A/S were worth $14,417,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Genmab A/S in the 4th quarter worth approximately $60,000. Aquatic Capital Management LLC acquired a new stake in Genmab A/S in the 4th quarter worth approximately $114,000. Finally, Blue Trust Inc. lifted its holdings in Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock worth $145,000 after purchasing an additional 4,666 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Stock Down 0.6%
Shares of NASDAQ GMAB opened at $21.88 on Friday. The business’s 50 day moving average is $21.18 and its two-hundred day moving average is $20.78. The company has a market cap of $14.04 billion, a P/E ratio of 12.43, a P/E/G ratio of 6.69 and a beta of 0.94. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $28.56.
Wall Street Analyst Weigh In
Several research firms recently weighed in on GMAB. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, July 12th. Truist Financial boosted their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. HC Wainwright restated a “buy” rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.80.
Get Our Latest Stock Report on Genmab A/S
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Why Pure Storage Is a Core Investment for the AI Era
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- What is the FTSE 100 index?
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.